Latest news with #ScottHutton
Yahoo
4 days ago
- Health
- Yahoo
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined. As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources. 'We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,' said Scott Hutton, CEO of Biodesix. 'Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.' 'APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,' said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. 'An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients . APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.' About APAPP APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Contacts: APAPP:Corinne Young, MSN, FNP, FCCPPresident & Founder, APAPPcorinne@ (719) 425-7040 Biodesix:Natalie St. Denis, Director Corporate (720) 925-9285
Yahoo
4 days ago
- Health
- Yahoo
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined. As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources. 'We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,' said Scott Hutton, CEO of Biodesix. 'Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.' 'APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,' said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. 'An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients . APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.' About APAPP APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Contacts: APAPP:Corinne Young, MSN, FNP, FCCPPresident & Founder, APAPPcorinne@ (719) 425-7040 Biodesix:Natalie St. Denis, Director Corporate (720) 925-9285Sign in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award
LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner. The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on employee feedback gathered through a third-party survey, administered by employee engagement technology partner, Energage. The confidential survey uniquely measures the employee experience and its component themes, including employees feeling respected & supported, enabled to grow, and empowered to execute, to name just a few key attributes of a top-performing workplace. 'I want to first recognize each of the Biodesix team members for their direct contributions in cultivating our high performing and fulfilling workplace culture,' said Scott Hutton, CEO & President of Biodesix, Inc. 'As one of only 150 companies to earn this recognition, it reinforces that Biodesix is an employer of choice and reflects our team's enthusiasm to continue building our unique culture. Thank you again to the team for their commitment to excellence in serving our healthcare customers, their patients, and our industry partners as we continue driving towards the Biodesix mission and vision.' This is the company's second consecutive year being recognized as a through comprehensive anonymous employee surveys on critical themes measuring employee engagement and workplace culture. Last year, Biodesix received the prestigious Inc. Magazine 2024 Best Workplaces award. 'In today's market, leaders must ensure they're cultivating a workplace where employees have a voice, and they are heard. Earning a Top Workplaces award is an exclusive badge of honor for companies, especially because it comes authentically from their employees,' said Eric Rubino, Energage CEO. 'That's something to be very proud of.' ABOUT BIODESIXBiodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences tools and diagnostics companies, and academic research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information on our culture and operating principles (), please see our website: ABOUT ENERGAGEEnergage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. For more information, visit or Contacts:Media:Natalie St. Denis, Director Corporate Communications, (720) 925-9285 Investors:Chris Brinzey, Partner, Westwicke +1 (339) 970-2843Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-02-2025
- Business
- Yahoo
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025. TD Cowen 45th Annual Health Care ConferenceFireside Chat Date: Wednesday, March 5, 2025Fireside Chat Time: 1:50 PM ETLocation: Boston, MA The presentation will be webcast live and available for replay under 'News & Events' in the Investors section of the Company's website at About Biodesix Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for pulmonology patients. The Nodify Lung® Nodule Risk Assessment evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The IQLung™ test portfolio for lung cancer patients supports treatment decisions across all stages of lung cancer and expedites personalized treatment. In addition, Biodesix collaborates with the world's leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc. Contacts: Media:Natalie St. Investors:Chris
